NEW YORK, Aug. 15 – Merck has acquired a non-exclusive license to Lexicon Genetics' gene-targeting technologies, bringing to 16 the total number of licensees for the technologies, Lexicon said on Wednesday.

Details of the agreement were not disclosed.

Lexicon Genetics, of The Woodlands, Texas, uses gene-knockout technology to identify genes of medical interest. In addition to licensing this technology, Lexicon uses it to develop its own drug-discovery efforts.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.

NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.

CNBC reports that there are thousands of genetic tests available for consumers to chose between.

In Nature this week: genomic analysis of ducks, whole-genome doubling among tumor samples, and more.